Prognostic significance of EZH2 expression in patients with digestive cancers: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 9, 2015, Pages 16043-16049

  Wang, Wei ^a   Wang, Feng ^a   Zong, Guangquan ^a   Liu, Renmin ^a   Zhang, Yufei ^a   Luan, Yang ^a   Xu, Lin ^a   Xuan, Ji ^a  

^a PLA Cancer Center   (China)

Author keywords

Colorectal cancer; Enhancer of zeste homolog 2; Esophageal cancer; Gastric cancer; Meta analysis; Prognosis

Indexed keywords

TRANSCRIPTION FACTOR EZH2;

ARTICLE; CANCER PROGNOSIS; COLORECTAL CANCER; DATA EXTRACTION; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUALITY CONTROL; STOMACH CANCER;

EID: 84946553417     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Wang JH, Chen XT, Wen ZS, Zheng M, Deng JM, Wang MZ, Lin HX, Chen K, Li J, Yun JP, Luo RZ, Song LB. High expression of GOLPH3 in eso-phageal squamous cell carcinoma correla-tes with poor prognosis. PLoS One 2012; 7: e45622.
3. Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng IO, Sun H, Qin L, Qiu S, Lee JM, Lo CM, Man K, Yang Y, Yang Y, Yang Y, Zhang Q, Zhu X, Li N, Wang Z, Ding G, Zhuang SM, Zheng L, Luo X, Xie Y, Liang A, Wang Z, Zhang M, Xia Q, Liang T, Yu Y, Cao X. Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma. Cancer Cell 2014; 25: 49-63.
4. He H, Wang C, Shen Z, Fang Y, Wang X, Chen W, Liu F, Qin X, Sun Y. Upregulated expression of C-X-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer. PLoS One 2013; 8: e71864.
5. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-9.
6. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100: 11606-11.
7. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG,Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-9.
8. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010; 18: 185-97.
9. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001; 323: 224-8.
10. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
11. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177-188.
13. Egger M, Smith GD, Schneider M. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
14. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
15. Benard A, Goossens-Beumer IJ, van Hoesel AQ, Horati H, Putter H, Zeestraten EC, van de Velde CJ, Kuppen PJ. Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer. PLoS One 2014; 9: e108265.
16. Ha SY, Kim SH. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma. Pathol Res Pract 2012; 208: 462-9.
17. He LJ, Cai MY, Xu GL, Li JJ, Weng ZJ, Xu DZ, Luo GY, Zhu SL, Xie D. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer. Asian Pac J Cancer Prev 2012; 13: 3173-8.
18. Kodach LL, Jacobs RJ, Heijmans J, van Noesel CJ, Langers AM, Verspaget HW,Hommes DW, Offerhaus GJ, van den Brink GR, Hardwick JC. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 2010; 31: 1567-75.
19. Lee H, Yoon SO, Jeong WY, Kim HK, Kim A, Kim BH. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer. Hum Pathol 2012; 43: 1704-10.
20. Liu YL, Gao X, Jiang Y, Zhang G, Sun ZC, Cui BB, Yang YM. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. J Cancer Res Clin Oncol 2015; 141: 661-669.
21. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006; 97: 484-91.
22. Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol 2010; 16: 2421-7.
23. Wang H, Wang M, Liang G, Wu D. Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients. J South Med Univ 2013; 33: 99-102.
24. Yamada A, Fujii S, Daiko H, Nishimura M, Chiba T, Ochiai A. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int J Oncol 2011; 38: 345-53.
25. Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S, Chinnaiyan AM. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007; 12: 419-31.
26. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27: 7274-84.
27. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-9.
28. Fujii S, Ito K, Ito Y, Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates runx3 by increasing histone H3 methylation. J Biol Chem 2008; 283: 17324-32.
29. Tonini T, D'Andrilli G, Fucito A, Gaspa L, Bagella L. Importance of Ezh2 polycomb protein in tu morigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol 2008; 214: 295-300.
30. Begg CB, Berlin JA. Publication bias. A problem in interpreting medical data. J R Stat Soc A 1988; 151: 419-463.